Exclusive special offer and discount title banner vector image

UNITED STATES ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET FORECAST 2024-2032

SCOPE OF THE REPORT

United States Antibody Drug Conjugates Contract Manufacturing Market by Phase (Clinical Phase, Commercial Phase) Market by Linker (Cleavable Linkers, Non-cleavable Linkers) Market by Condition (Myeloma, Lymphoma, Breast Cancer, Other Conditions)


MARKET OVERVIEW

The United States antibody drug conjugates contract manufacturing market is projected to grow at a CAGR of 12.29% over the forecast period of 2024-2032. It is positioned to reach a revenue of $6985.72 million by 2032

The United States antibody drug conjugates contract manufacturing market is experiencing substantial growth, boosted by the increasing demand for ADCs in the healthcare sector. The prevalence of complex diseases like cancer continues to increase, leading to a growing need for targeted and effective treatment options. This trend drives the demand for ADCs and spurs market expansion in the United States.

Another important trend shaping this market is the growing emphasis on ADC quality and regulatory compliance. Stringent regulatory standards govern the production and distribution of biopharmaceuticals in the United States. Manufacturers of ADCs must prioritize quality control measures and adhere to regulatory guidelines to ensure the safety and efficacy of their products. This focus on quality and compliance has become a distinctive feature of the ADC manufacturing domain in the country.

United States Antibody Drug Conjugates Contract Manufacturing Market

To Know More About This Report, Request a Free Sample Copy

However, challenges such as the high cost of ADC development and manufacturing persist in this market. The complex processes involved in developing ADCs, including drug conjugation and formulation, contribute to elevated production costs. This factor can pose challenges for smaller pharmaceutical companies looking to enter the market. It highlights the need for cost-effective manufacturing solutions and strategic partnerships to navigate these challenges effectively.

Additionally, the United States ADC contract manufacturing industry faces increasing competition from biosimilar ADCs and generic drugs. More companies entering the biopharmaceutical space and developing alternative versions of ADCs intensify competition. This leads to pricing pressures and necessitates differentiation through innovation and superior quality assurance measures. These dynamics shape the competitive sphere of the ADC contract manufacturing market in the United States. They drive companies to innovate and differentiate their offerings to effectively meet ADC products demand.

The United States antibody drug conjugates contract manufacturing market segmentation includes the market by phase, linker, and condition. The condition segment is further divided into myeloma, lymphoma, breast cancer, and other conditions. Myeloma, a type of blood cancer affecting plasma cells, has seen growing research and development efforts to develop targeted ADC therapies. Contract manufacturing organizations (CMOs) specializing in myeloma-targeted ADCs play a vital role in meeting the demand for effective treatments in this field.

Lymphoma, another sub-segment within the ADC contract manufacturing market, encompasses various subtypes of blood cancers that affect lymphocytes. The development of ADCs targeting lymphoma subtypes reflects the ongoing innovation in cancer therapeutics. Manufacturers focusing on lymphoma-specific ADCs contribute to expanding treatment options and improving patient outcomes in the lymphoma patient population.

Breast cancer, a prevalent and diverse disease with different subtypes, is also a significant sub-segment in the market. ADCs designed to target specific molecular markers in breast cancer cells offer personalized treatment approaches. Contract manufacturers specializing in breast cancer-targeted ADCs play a crucial role in advancing precision medicine. They enhance therapeutic options for patients with breast cancer by developing targeted treatments that address specific molecular markers in breast cancer cells.

Some of the leading players in the United States antibody drug conjugates contract manufacturing market include AbbVie Inc (AbbVie Contract Manufacturing), Merck KGaA, Catalent Inc, etc. 

Catalent Inc is a leading pharmaceutical manufacturing company renowned for its specialized development and manufacturing solutions. They cover a wide range of products, including drugs, biologics, cell and gene therapies, vaccines, and consumer health products. Their extensive portfolio encompasses respiratory, injectable, and oral delivery technologies. With a global presence spanning 52 facilities across the Americas, Europe, and Asia-Pacific, Catalent Inc is headquartered in Somerset, New Jersey, USA.

REPORT SYNOPSIS

REPORT SCOPEDETAILS
Market Forecast Years2024-2032
Base Year2023
Market Historical Years2018-2022
Forecast Units

Revenue ($ Million)

Segments Analyzed
Phase, Linker, and Condition
Countries AnalyzedUnited States
Companies AnalyzedAbbVie Inc (AbbVie Contract Manufacturing), Merck KGaA, Catalent Inc, Cambrex Corporation, Piramal Pharma Solutions
TABLE OF CONTENTS
  1. RESEARCH SCOPE & METHODOLOGY
    1. STUDY OBJECTIVES
    2. METHODOLOGY
    3. ASSUMPTIONS & LIMITATIONS
  2. EXECUTIVE SUMMARY
    1. MARKET SIZE & ESTIMATES
    2. COUNTRY SNAPSHOT
    3. COUNTRY ANALYSIS
    4. SCOPE OF STUDY
    5. CRISIS SCENARIO ANALYSIS
    6. MAJOR MARKET FINDINGS
      1. INCREASING COLLABORATION BETWEEN KEY CONTRACT MANUFACTURERS (CMOS)
      2. CHALLENGES IN NAVIGATING COMPLEX REGULATORY REQUIREMENTS
  3. MARKET DYNAMICS
    1. KEY DRIVERS
      1. RISING DEMAND FOR TARGETED THERAPIES
      2. GROWING INCLINATION TOWARDS CONTRACT MANUFACTURING COMPANIES AS AN ECONOMICAL CHOICE
      3. SURGING GLOBAL CANCER INCIDENCE
      4. ADVANCEMENTS IN DRUG CONJUGATION TECHNOLOGIES
    2. KEY RESTRAINTS
      1. HIGH COST OF ADC (ANTIBODY DRUG CONJUGATES) DEVELOPMENT AND MANUFACTURING
      2. INCREASING COMPETITION FROM BIOSIMILAR ADC (ANTIBODY DRUG CONJUGATES) AND GENERIC DRUGS
      3. STRINGENT REGULATORY REQUIREMENTS
  4. KEY ANALYTICS
    1. KEY MARKET TRENDS
      1. RISING DEMAND FOR ADCS
      2. GROWING FOCUS ON ADC QUALITY AND REGULATORY COMPLIANCE
    2. PESTLE ANALYSIS
      1. POLITICAL
      2. ECONOMICAL
      3. SOCIAL
      4. TECHNOLOGICAL
      5. LEGAL
      6. ENVIRONMENTAL
    3. PORTER’S FIVE FORCES ANALYSIS
      1. BUYERS POWER
      2. SUPPLIERS POWER
      3. SUBSTITUTION
      4. NEW ENTRANTS
      5. INDUSTRY RIVALRY
    4. GROWTH PROSPECT MAPPING 
      1. GROWTH PROSPECT MAPPING FOR UNITED STATES
    5. MARKET CONCENTRATION ANALYSIS
    6. KEY BUYING CRITERIA
      1. EXPERTISE AND EXPERIENCE
      2. MANUFACTURING CAPACITY
      3. REGULATORY COMPLIANCE
      4. QUALITY CONTROL
      5. COST
    7. REGULATORY FRAMEWORK
  5. MARKET BY PHASE
    1. CLINICAL PHASE
      1. MARKET FORECAST FIGURE
      2. SEGMENT ANALYSIS
    2. COMMERCIAL PHASE
      1. MARKET FORECAST FIGURE
      2. SEGMENT ANALYSIS
  6. MARKET BY LINKER
    1. CLEAVABLE LINKERS
      1. MARKET FORECAST FIGURE
      2. SEGMENT ANALYSIS
    2. NON-CLEAVABLE LINKERS
      1. MARKET FORECAST FIGURE
      2. SEGMENT ANALYSIS
  7. MARKET BY CONDITION
    1. MYELOMA
      1. MARKET FORECAST FIGURE
      2. SEGMENT ANALYSIS
    2. LYMPHOMA
      1. MARKET FORECAST FIGURE
      2. SEGMENT ANALYSIS
    3. BREAST CANCER
      1. MARKET FORECAST FIGURE
      2. SEGMENT ANALYSIS
    4. OTHER CONDITIONS
      1. MARKET FORECAST FIGURE
      2. SEGMENT ANALYSIS
  8. COMPETITIVE LANDSCAPE
    1. KEY STRATEGIC DEVELOPMENTS
      1. MERGERS & ACQUISITIONS
      2. PRODUCT LAUNCHES & DEVELOPMENTS
      3. PARTNERSHIPS & AGREEMENTS
    2. COMPANY PROFILES
      1. ABBVIE INC (ABBVIE CONTRACT MANUFACTURING)
        1. COMPANY OVERVIEW
        2. SERVICES LIST
        3. STRENGTHS & CHALLENGES
      2. CAMBREX CORPORATION
        1. COMPANY OVERVIEW
        2. SERVICES LIST
      3. CATALENT INC
        1. COMPANY OVERVIEW
        2. SERVICES LIST
        3. STRENGTHS & CHALLENGES
      4. MERCK KGAA
        1. COMPANY OVERVIEW
        2. SERVICES LIST
        3. STRENGTHS & CHALLENGES
      5. PIRAMAL PHARMA SOLUTIONS
        1. COMPANY OVERVIEW
        2. SERVICES LIST
        3. STRENGTHS & CHALLENGES

LIST OF TABLES

TABLE 1: MARKET SNAPSHOT – ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING

TABLE 2: REGULATORY FRAMEWORK

TABLE 3: UNITED STATES ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, BY PHASE, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 4: UNITED STATES ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, BY PHASE, FORECAST YEARS, 2024-2032 (IN $ MILLION)

TABLE 5: UNITED STATES ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, BY LINKER, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 6: UNITED STATES ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, BY LINKER, FORECAST YEARS, 2024-2032 (IN $ MILLION)

TABLE 7: UNITED STATES ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, BY CONDITION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 8: UNITED STATES ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, BY CONDITION, FORECAST YEARS, 2024-2032 (IN $ MILLION)

TABLE 9: LIST OF MERGERS & ACQUISITIONS

TABLE 10: LIST OF PRODUCT LAUNCHES & DEVELOPMENTS

TABLE 11: LIST OF PARTNERSHIPS & AGREEMENTS

LIST OF FIGURES

FIGURE 1: KEY MARKET TRENDS

FIGURE 2: PORTER’S FIVE FORCES ANALYSIS

FIGURE 3: GROWTH PROSPECT MAPPING FOR UNITED STATES

FIGURE 4: MARKET CONCENTRATION ANALYSIS

FIGURE 5: KEY BUYING CRITERIA

FIGURE 6: UNITED STATES ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, GROWTH POTENTIAL, BY PHASE, IN 2023

FIGURE 7: UNITED STATES ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, BY CLINICAL PHASE, 2024-2032 (IN $ MILLION)

FIGURE 8: UNITED STATES ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, BY COMMERCIAL PHASE, 2024-2032 (IN $ MILLION)

FIGURE 9: UNITED STATES ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, GROWTH POTENTIAL, BY LINKER, IN 2023

FIGURE 10: UNITED STATES ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, BY CLEAVABLE LINKERS, 2024-2032 (IN $ MILLION)

FIGURE 11: UNITED STATES ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, BY NON-CLEAVABLE LINKERS, 2024-2032 (IN $ MILLION)

FIGURE 12: UNITED STATES ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, GROWTH POTENTIAL, BY CONDITION, IN 2023

FIGURE 13: UNITED STATES ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, BY MYELOMA, 2024-2032 (IN $ MILLION)

FIGURE 14: UNITED STATES ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, BY LYMPHOMA, 2024-2032 (IN $ MILLION)

FIGURE 15: UNITED STATES ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, BY BREAST CANCER, 2024-2032 (IN $ MILLION)

FIGURE 16: UNITED STATES ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, BY OTHER CONDITIONS, 2024-2032 (IN $ MILLION)

FAQ’s